Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension
- 1 August 2001
- journal article
- clinical trial
- Published by Elsevier in Gastroenterology
- Vol. 121 (2) , 389-395
- https://doi.org/10.1053/gast.2001.26295
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosisPublished by Elsevier ,1995
- The treatment of portal hypertension: A meta-analytic reviewHepatology, 1995
- Beta-Adrenergic–Antagonist Drugs in the Prevention of Gastrointestinal Bleeding in Patients with Cirrhosis and Esophageal VaricesNew England Journal of Medicine, 1991
- Propranolol Compared with Propranolol plus Isosorbide-5-Mononitrate for Portal Hypertension in CirrhosisAnnals of Internal Medicine, 1991
- Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhageGastroenterology, 1990
- Acute and chronic hemodynamic effects of propranolol in unselected cirrhotic patientsHepatology, 1987
- Short–Term Effects of Propranolol on Portal Venous PressureHepatology, 1986
- Effects of Propranolol on Azygos Venous Blood Flow and Hepatic and Systemic Hemodynamics in CirrhosisHepatology, 1984
- Propranolol for Prevention of Recurrent Gastrointestinal Bleeding in Patients with CirrhosisNew England Journal of Medicine, 1981
- PROPRANOLOL—A MEDICAL TREATMENT FOR PORTAL HYPERTENSION?The Lancet, 1980